Damage limitation therapy not an alternative to antibiotics

Image
IANS London
Last Updated : Jan 23 2014 | 6:22 PM IST

Damage limitation therapies that control the symptoms caused by a bug or virus in the body rather than killing it at the first place, may not be effective in the long term, scientists have found.

Damage limitation therapies focus on enabling the patient to tolerate disease and buy the immune system valuable time to get rid of the infection naturally.

Researchers at the Universities of Edinburgh and Liverpool in Britain created a mathematical model to look at how damage limitation drugs could affect how infections spread and evolve.

People given damage limitation therapies may appear healthy, but carry high levels of infection and so may be more likely to pass on disease, said the study published in the journal PLoS Biology.

"In treating infections with drugs, we change their environment, but bacteria and other infectious agents are incredibly good at adapting to their environment," said Pedro Vale of University of Edinburgh's school of biological sciences.

The researchers found that for certain infections, where the symptoms are not linked to the spread of disease, these drugs may prevent disease from evolving too quickly.

However, people with lesser symptoms could remain undiagnosed and add to the spread of disease, the study said.

"Damage limitation therapies may be a useful alternative to antibiotics, but we should be cautious, and investigate their potential long-term consequences," Vale added.

-Indo-Asian News Service

gb/na/rd

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 23 2014 | 6:16 PM IST

Next Story